Heat shock proteins, such as HSP40, HSP60, HSP70 and HSP90, are known as molecular chaperones because they play a role in helping proteins function properly when cells are under stress. The heat shock response protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes (the cell’s recycling system), which could otherwise lead to toxicity and disease.
Our work is focused on making use of the cell-protective properties of HSP70 to create new therapies for rare neurodegenerative diseases.
Orphazyme A/S Company announcement No. 22/2021 Company Registration No. 32266355 Copenhagen – October 5 , 20 2 1 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is
Orphazyme A/S Company announcement No. 21/2021 CVR No.: 32266355 Copenhagen, Denmark, August 31 , 202 1 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company, today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2021.
Orphazyme A/S Investor news No. 08/2021 Company Registration No. 32266355 Copenhagen – August 2 5 , 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces that the Company will host an investor call during which Management will present the Interim
Our Research
For Investors & Media
Working at Orphazyme